Drug Trial Radar · NCT05887492
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
Jun 12, 2023
Primary completion
Sep 22, 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Tango Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.
Conditions
- Non Small Cell Lung Cancer
- Solid Tumors, Adult
- Lung Cancer
- Lung Adenocarcinoma
Interventions
TNG260Drug
CoREST inhibitor, administered orally
PembrolizumabDrug
Pembrolizumab, an anti-PD-1 antibody, administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the MTD and RP2D(s) (Phase 1 only)Time frame: 42 days
- Measure antitumor activity using RECIST 1.1 (Phase 2 only)Time frame: 12 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
UCLA Hematology/Oncology
Santa Monica, California
SCRI at HealthOne
Denver, Colorado
Florida Cancer Specialists
Sarasota, Florida
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
START MidWest
Grand Rapids, Michigan
NYU Langone Hematology Oncology Associates-Mineola
Mineola, New York
New York University Langone Health
New York, New York
Sarah Cannon Tennessee Oncology
Nashville, Tennessee
US Oncology Investigational Products Center
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
NEXT Oncology Virginia
Fairfax, Virginia
US Oncology Investigational Products Center
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.